Dr. Vivaldi, is EVP, Chief global Therapeutic Operations Officer, of Bioverativ, a Sanofi Company focused on hemophilia, cold agglutinin disease and other rare blood disorders.  Previously, he was Chief Commercial Officer at Spark Therapeutics a gene therapy company, which developed the first U.S. FDA approved and directly administered gene therapy targeting mutations in a specific gene. At Spark, he built the global structure to commercialize gene therapy products, the Medical Affairs organization, and the Patient Advocacy group. Before Spark Therapeutics, Rogerio was co-founder, President and CEO of Minerva Neurosciences, a clinical-stage biopharmaceutical company developing and commercializing multiple product candidates for treatment of neuropsychiatric diseases. Prior to Minerva, he led the rare disease business at Genzyme Corporation, where he earned a reputation as a passionate advocate for patients. He served as president of the Rare Diseases business and the Renal & Endocrine group, and as senior vice president and general manager of the company’s Latin America group.  Dr. Vivaldi also enjoyed 18 years in private practice, specializing in diabetes and endocrinology. He received his medical degree from Universidade do Rio de Janeiro (UNIRIO) Medical School, and completed his residency in endocrinology at Universidade do Estado do Rio de Janeiro (UERJ) and his fellowship at Mount Sinai Hospital Center in New York in the department of genetics, with an emphasis on Gaucher disease. He received his MBA degree from COPPEAD, Universidade Federal do Rio de Janeiro (UFRJ).